Clinical trials: Proton Pump Inhibitors
Healthy Volunteers
A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults
The main aim of this study is to find out how zasocitinib (TAK-279) interacts with other medicines taken by mouth (orally). This will be examined by how the body processes medicines, which is called pharmacokinetics or PK.
- Trial name
- NCT06793943
- Testing
- Zasocitinib, COC, Metformin
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Participants
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
This is a single-center, open-label, randomized, four-period, six-sequence study with a planned enrollment of 24 healthy participants.
- Trial name
- NCT07643272
- Testing
- HMPL-760, Rabeprazole and HMPL-760
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Esophagitis
Risk of Cancer Among Pantoprazole Users
The primary objective is to assess whether the risk of gastric cancer is increased in pantoprazole users compared to users of other proton pump inhibitors.
- Trial name
- NCT01322633
- Testing
- Does not apply
- Volunteers
- 61,864 people
- Sponsor
- Pfizer
Healthy
Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)
This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy…
- Trial name
- NCT07888569
- Testing
- DZD8586, Rabeprazole
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Healthy
Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
To investigate the effect of acid reducing agents (an antacid and an H2-receptor antagonist and a proton pump inhibitor) on palbociclib bioavailability in the presence of food.
- Trial name
- NCT02097329
- Testing
- palbociclib commercial free base, famotidine, rabeprazole
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Amyotrophic Lateral Sclerosis
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
This study will evaluate the pharmacokinetics and safety of GDC-0134 in healthy female volunteers of non-childbearing potential.
- Trial name
- NCT03237741
- Testing
- Reference capsule GDC-0134, Prototype capsule GDC-0134, rabeprazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Hypergastrinaemia
Effects of YF476 and Rabeprazole on Gastric Function
The primary objectives are to find out in healthy subjects if: YF476 prevents the ECL-cell hyperplasia induced by repeated doses of rabeprazole - a proton pump inhibitor; YF476 also prevents rebound hyperacidity after stopping…
- Trial name
- NCT01699113
- Testing
- YF476, Rabeprazole
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Non-alcoholic Fatty Liver Disease
Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
The primary objective of this trial is to investigate the relative Bioavailability (BA) of tablet formulation of Dabigatran etexilate (DE) with and without co-administration of rabeprazole in healthy male subjects.
- Trial name
- NCT03143166
- Testing
- Dabigatran Etexilate, Rabeprazol sodium
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Nonfatal Myocardial Infarction, Coronary Death
Association Between Low Dose Acetylsalicylic Acid (ASA) and Proton Pump Inhibitors and Risk of Acute Myocardial Infarction or Coronary Heart Disease Death
The purpose of this study is to estimate the risk of myocardial infarction (MI)/coronary death associated with use of monotherapy low dose ASA (single antiplatelet) as well as concomitant use of monotherapy low dose ASA and…
- Trial name
- NCT01360073
- Where
- 2 sites in Spain, Sweden
- Volunteers
- 42,542 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole
This is a two-part study to be conducted at single study center, (additional center(s) may be selected if needed) to assess the safety, tolerability, PK and PD parameters for a new SDD formulation of CC-11050 in healthy subjects.
- Trial name
- NCT04139226
- Testing
- CC-11050
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults
The purpose of this study is to evaluate the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults.
- Trial name
- NCT02638116
- Testing
- Ibrutinib, Omeprazole
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Gastroesophageal Reflux
Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) Treatment
The primary objective of the study is to describe the change in GerdQ sum scores, after a 4-week period of systematic treatment with PPIs(using GerdQ questionnaire).
- Trial name
- NCT01103804
- Where
- 19 sites in Romania
- Volunteers
- 952 people
- Sponsor
- AstraZeneca
Healthy
Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)
Fixed sequence, 2-period crossover study to compare the pharmacokinetic profiles of Palbociclib in absence and presence of prior administration of proton pump inhibitor Rabeprazole.
- Trial name
- NCT01918176
- Testing
- Palbociclib alone, Palbociclib + Rabeprazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
GERD, Gastroesophageal Reflux
Observational Study of Anti-Reflux Surgery
The Anti-Reflux Surgical Study has been established to: Collect data about anti-reflux surgical treatment options (magnetic sphincter augmentation and Fundoplication) in everyday clinical practice Track the clinical course of…
- Conditions
- GERD, Gastroesophageal Reflux, Gastro Esophageal Reflux
- Trial name
- NCT01624506
- Where
- 21 sites in Austria, Germany and 2 more
- Volunteers
- 760 people
- Sponsor
- Torax Medical Incorporated
GERD, Acid Reflux Disease
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
- Conditions
- GERD, Acid Reflux Disease, Heartburn, Regurgitation
- Trial name
- C27 (NCT00703534)
- Testing
- AZD3355, Gelusil®
- Where
- 84 sites in United States
- Volunteers
- 478 people
- Sponsor
- AstraZeneca
Healthy
Surufatinib DDI With a PPI and a CYP3A Inducer
The purpose of this is to evaluate the effect of proton pump inhibitor (rabeprazole) and the effect of a CYP3A inducer (rifampin) on the pharmacokinetics of Surufatinib.
- Trial name
- NCT04510649
- Testing
- Part A, Part B
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hutchison Medipharma Limited
Healthy Volunteers
A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation
This study is intended to establish the bioequivalence (BE) of single 100 mg doses of glasdegib administered under fasted conditions to healthy volunteers as the ICH formulation compared to the Phase 2 formulation.
- Trial name
- B1371026 (NCT03130556)
- Testing
- Glasdegib, High Fat, High Calorie Meal, Rabeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
GERD
Evaluation of Safety and Effectiveness of the RefluxStop Device in the Management of GERD
Prospective, open-label, multi-centre, single arm treatment only trial to evaluate the safety and effectiveness of RefluxStop for the treatment of GERD.
- Trial name
- NCT02759094
- Testing
- Treatment with RefluxStop
- Where
- 4 sites in Hungary, Serbia
- Volunteers
- 50 people
- Sponsor
- Implantica CE Reflux Ltd.
Osteoarthritis, Rheumatoid Arthritis
Assessment of NSAID-treated Patients Adherence to Co-prescribed Proton Pump Inhibitor (PPI)
The primary objective of this cross-sectional observational real life study is to investigate the patient reported adherence to PPI, when prescribed as prevention of NSAID associated GI Ulcers to patients prescribed a NSAID.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- CONVOY (NCT01519375)
- Where
- 8 sites in Sweden
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)
The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of…
- Trial name
- NCT00992589
- Testing
- Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.